Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIRâ"¢ (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Accessibility Statement Skip NavigationTopline data of investigatorinitiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was well-tolerated with no dose-limiting toxicities observedCRANFORD, N.J., March 4, 2026 ...